gastric cancer
Conditions
Interventions
CtDNA detection group: CtDNA detection
Sponsors
Department of gastrointestinal surgery, the First Affiliated Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. It is expected to complete radical D2 lymph node dissection (the number of lymph nodes examined must be at least 15 to ensure the quality of the operation). 2. Physical condition and organ function allow large abdominal surgery. 3. Willing and able to follow the protocol during the study. 4. Provide written informed consent before entering the study screening, and the patient has learned that he can withdraw from the study at any time without any loss. 5. Patients aged 18-70 years with gastric adenocarcinoma confirmed by pathology before operation. The total course of chemotherapy and adjuvant chemotherapy were 6 months, and the survival period was expected to be > 6 months. 7. No other serious concomitant diseases and good organ function. 8. There are no medical contraindications that seriously affect anesthesia and surgery. 9. Have not received anti-tumor treatment (such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy); 10. The 8th Edition AJCC stage is ct3-4an1-3m0 gastric cancer patients. 11. The blood routine examination standard shall meet the following standards: a WBC>4.0 × 10/L b. ANC>1.5 × 10/L c. ANC >= 1.5 × 10^9/L d. HB >= 80 g/L e. PLT >= 100 × 10^9/L 12. Biochemical examination shall meet the following standards: a TBIL= 50 mL/ min (Cockcroft Gault formula). 13. No history of upper abdominal surgery (except laparoscopic cholecystectomy); No history of peritonitis and pancreatitis. 14. There are no other serious diseases that make the survival time 60; ECoG score: 0-2. 16. No history of other tumors
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women who are in the reproductive period and do not take effective contraceptive measures. 2. Complicated with serious medical diseases or conditions: such as clinically serious (i.e. active) heart disease, serious and uncontrolled medical diseases and infections, serious uncontrollable digestive system disorders, serious electrolyte disorders, active disseminated intravascular coagulation, major organ failure, such as decompensated heart, lung, liver, kidney failure, peripheral neuropathy, etc., unable to tolerate D2 radical gastrectomy. 3. Organ transplantation requires immunosuppressive therapy. 4. Serious uncontrolled repeated infection or other serious uncontrolled concomitant diseases. 5. History of other malignant tumors within 5 years from the start of the trial, except cured skin basal cell carcinoma and cervical carcinoma in situ. 6. Patients without self-knowledge ability and mental disorders. 7. Have a history of organ transplantation (including bone marrow autotransplantation and peripheral stem cell transplantation). 8. Use other test drugs at the same time or in other clinical trials. 9. Those who have received biological therapy or other anti-cancer traditional Chinese medicine with an interval of less than 4 weeks. 10. HER-2 test is positive or esophageal gastric junction adenocarcinoma, patients who are willing to receive Herceptin treatment or patients with indications and willingness to receive immunotherapy; 11. Postoperative chemotherapy is not acceptable. 12. Patients with peripheral neuropathy nct-ctcae >= grade 2; 13. Tumor recidivism surrounding organs (T4b) or combined with distant metastasis. 14. For those who are allergic to the drugs in this study protocol, the researcher determines that they are not suitable for participating in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of blood ctDNA value; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progress Free Survival; | — |
Countries
China
Contacts
Public ContactJigang
Outcome results
None listed